FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:197-199 January 10, 2008 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Moore, A. Related Article by Hayes, D. F. PubMed Citation

To the Editor: Trastuzumab and aromatase inhibitors — current standard agents for HER2-positive breast cancer and estrogen-receptor–positive postmenopausal breast cancer, respectively — were not included in the Cancer and Leukemia Group B (CALGB) trial of adjuvant treatment. Thus, in their report on HER2 and response to paclitaxel in women with node-positive breast cancer, Hayes et al. (Oct. 11 issue)¹ can make no conclusion about the usefulness of the addition of paclitaxel in the current standard combination of drugs.

Dimitrios H. Roukos, M.D.
Ioannina University School of Medicine
Ioannina 45110, Greece
droukos@cc.uoi.gr

1. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-1506. [Free Full Text]

This article has been cited by other articles:

• Mehta, R. S., Jackson, D., Schubbert, T. (2009). Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor-Positive and Hormone Receptor-Negative Breast Cancer. JCO 27: 3067-3068 [Full Text]  
• Roukos, D. H. (2009). Twenty-One-Gene Assay: Challenges and Promises in Translating Personal Genomics and Whole-Genome Scans Into Personalized Treatment of Breast Cancer. JCO 27: 1337-1338 [Full Text]